MIL induces DNA damage through topoisomerase II inhibition, activating the NF-κB pathway in a pro-apoptotic role; it enhances ATM/IKK/NF-κB signaling, leading to apoptosis even in drug-resistant ovarian cancer models. Here, NFKB1 is linked to ovarian carcinoma.